JP6792420B2 - 膣炎の治療 - Google Patents

膣炎の治療 Download PDF

Info

Publication number
JP6792420B2
JP6792420B2 JP2016220187A JP2016220187A JP6792420B2 JP 6792420 B2 JP6792420 B2 JP 6792420B2 JP 2016220187 A JP2016220187 A JP 2016220187A JP 2016220187 A JP2016220187 A JP 2016220187A JP 6792420 B2 JP6792420 B2 JP 6792420B2
Authority
JP
Japan
Prior art keywords
vaginal
test
zeolite
culture
cultures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016220187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017088603A (ja
JP2017088603A5 (https=
Inventor
ガストン・グロック
Original Assignee
グロック・ヘルス・サイエンス・アンド・リサーチ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グロック・ヘルス・サイエンス・アンド・リサーチ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グロック・ヘルス・サイエンス・アンド・リサーチ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2017088603A publication Critical patent/JP2017088603A/ja
Publication of JP2017088603A5 publication Critical patent/JP2017088603A5/ja
Application granted granted Critical
Publication of JP6792420B2 publication Critical patent/JP6792420B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016220187A 2015-11-12 2016-11-11 膣炎の治療 Expired - Fee Related JP6792420B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194288.5 2015-11-12
EP15194288.5A EP3167890A1 (de) 2015-11-12 2015-11-12 Behandlung von vaginitis

Publications (3)

Publication Number Publication Date
JP2017088603A JP2017088603A (ja) 2017-05-25
JP2017088603A5 JP2017088603A5 (https=) 2019-10-17
JP6792420B2 true JP6792420B2 (ja) 2020-11-25

Family

ID=54542054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016220187A Expired - Fee Related JP6792420B2 (ja) 2015-11-12 2016-11-11 膣炎の治療

Country Status (9)

Country Link
US (1) US20170136060A1 (https=)
EP (2) EP3167890A1 (https=)
JP (1) JP6792420B2 (https=)
KR (1) KR102335607B1 (https=)
CN (1) CN106974932B (https=)
AU (1) AU2016247097B2 (https=)
CA (1) CA2947570C (https=)
ES (1) ES2719223T3 (https=)
TR (1) TR201904382T4 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3524055A1 (de) * 2018-02-08 2019-08-14 BCSK Biocid GmbH Antibakterielles und spermizides gleitmittel
US20230407365A1 (en) * 2022-06-21 2023-12-21 Pamela Miles Diagnostic tool for screening the impact of product ingredients for urogenital microbiomes therapies
CN116059177A (zh) * 2022-12-14 2023-05-05 迪沙药业集团有限公司 一种克林霉素磷酸酯组合物及其制备方法
CN117535208B (zh) * 2024-01-04 2024-03-29 四川厌氧生物科技有限责任公司 一种卷曲乳杆菌及其在女性生殖道健康中的应用
JP7813333B1 (ja) * 2024-11-08 2026-02-12 日本食品化工株式会社 膣常在菌叢バランス改善剤及び膣用組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6353146B1 (en) * 1998-04-20 2002-03-05 Playtex Products, Inc. Fibrous articles having odor adsorbtion ability and method of making same
ES2165139T3 (es) * 1998-04-30 2002-03-01 Vesely Renata Maria Cavaliere Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales.
EP1316530B1 (de) * 1999-04-26 2004-12-15 Tihomir Lelas Mikronisierte Zoelithe zur Verwendung als pharmazeutisches Mittel
KR20060128125A (ko) * 2005-06-09 2006-12-14 인하대학교 산학협력단 만델산을 유효성분으로 함유하는 질염 치료제
WO2007054085A2 (de) * 2005-11-11 2007-05-18 Ljubicic, Mijo Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum
SI2040837T1 (sl) 2006-07-04 2012-10-30 Gaston Glock Postopek za odločenje težkih kovin
CN101594888A (zh) * 2006-12-15 2009-12-02 欧兰益生公司 含有产乳酸细菌的吸收制品
WO2009133413A1 (en) * 2008-04-28 2009-11-05 Novatech D.O.O. Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism
EP2358642B2 (de) * 2008-11-21 2022-12-07 Froximun AG Klinoptilolith oder klinoptilolithhaltige gemische
KR101198572B1 (ko) * 2010-07-09 2012-11-06 경희대학교 산학협력단 미생물 감염증 치료 또는 개선용 조성물

Also Published As

Publication number Publication date
EP3167891A1 (de) 2017-05-17
CN106974932A (zh) 2017-07-25
EP3167890A1 (de) 2017-05-17
TR201904382T4 (tr) 2019-04-22
BR102016026252A2 (pt) 2017-05-23
JP2017088603A (ja) 2017-05-25
CA2947570C (en) 2021-08-10
CN106974932B (zh) 2021-05-04
ES2719223T3 (es) 2019-07-09
US20170136060A1 (en) 2017-05-18
AU2016247097B2 (en) 2021-12-02
KR102335607B1 (ko) 2021-12-06
EP3167891B1 (de) 2019-01-23
KR20170055932A (ko) 2017-05-22
AU2016247097A1 (en) 2017-06-01
CA2947570A1 (en) 2017-05-12

Similar Documents

Publication Publication Date Title
JP6792420B2 (ja) 膣炎の治療
Miko et al. The role of hydrogen-peroxide (H2O2) produced by vaginal microbiota in female reproductive health
Matsubara et al. Probiotics as antifungals in mucosal candidiasis
CN110656060B (zh) 多联乳杆菌组合物及其在女性阴道健康中的应用
US12303538B2 (en) High potency stable formulations of vaginal lactobacillus
US12390489B2 (en) Use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli
Aboualigalehdari et al. Anti-biofilm Properties of Peganum harmala against Candida albicans
Huang et al. Antimicrobial substances and mechanisms of Lactobacillus rhamnosus against Gardnerella vaginalis
US10456430B1 (en) Lactobacillus composition for prevention and treatment of bacterial vaginosis
Hassan et al. Zinc Oxide nanoparticles and curcumin affect some virulence genes of Staphylococcus aureus and Candida albicans, the cause of sub-clinical mastitis in buffalo
Servin et al. Probiotic potentials of Lactic acid bacteria isolated from vaginal swabs on selected genital pathogens.
Zare et al. The effect of oral cinnamon capsule on the treatment and recurrence of Candidal vaginitis: a double-blind randomized clinical trial
Patole Apple cider vinegar: Effective adjuvant treatment for aerobic vaginitis
BR102016026252B1 (pt) Uso de clinoptilolita no tratamento de vaginite
Mollazadeh-Narestan et al. Comparison of the Efficacy of Honey and Clotrimazole Cream in the Vulvovaginal Candidiasis Treatment: A Systematic Review and Metaanalysis
Happel Evaluation of probiotic and vaginal Lactobacillus species for the treatment of bacterial vaginosis and promotion of vaginal health in South African women
Fatima et al. Antimicrobial Activity of Saccharomyces cerevisiae against Candida spp. Associated to Vulvovaginal Candidiasis
To From Relapse to Restoration: Insights into the Immunopathology of Bacterial Vaginosis (BV) in Women of Reproductive Age
CA3068958C (en) High potency stable formulations of vaginal lactobacillus
Vicariotto et al. Improvement of Bacterial Vaginosis and Vulvovaginal Candidiasis with a New Lactobacillus Strains Association: A Pilot Study

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190717

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201106

R150 Certificate of patent or registration of utility model

Ref document number: 6792420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees